A breakthrough in lung cancer treatment may be on the horizon. Scientists at VCU Massey Comprehensive Cancer Center have uncovered a powerful combination therapy leveraging sotorasib—an FDA-approved drug in the market—and an experimental drug called FGTI-2734, which could make precision medicine more effective for patients with a highly resistant form of lung cancer. The study, featured on the cover of the Journal of Thoracic Oncology, reveals a potential game-changer for patients battling tumors with the KRAS G12C mutation—a driver in about 14% of non-small cell lung cancers.

TTUHSC student researchers recently participated in the university’s 37th Student Research Week, organized by the TTUHSC Graduate School of Biomedical Sciences. The event allows TTUHSC students to showcase their research and hear presentations from distinguished national speakers related to the year’s theme. TTUHSC’s Department of Cell Physiology and Molecular Biophysics hosted the 2025 event, and “Let’s Get Biophysical” was the theme to highlight the host department's focus on biophysical techniques, particularly in membrane protein research.